TO

TORII PHARMACEUTICAL CO., LTD.

A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.

4551 | T

Overview

Corporate Details

ISIN(s):
JP3635800000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目4番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Torii Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and marketing of ethical drugs. The company focuses its business activities on key therapeutic areas, including renal diseases and hemodialysis, skin diseases, and allergies. Its product portfolio addresses conditions such as atopic dermatitis and pruritus associated with chronic kidney disease. Following a tender offer completed in 2025, the company operates as a subsidiary of Shionogi & Co., Ltd.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-07 06:04
Registration Form
確認書
Japanese 9.3 KB
2025-08-07 06:01
Interim Report
半期報告書-第134期(2025/01/01-2025/12/31)
Japanese 215.6 KB
2025-07-10 08:30
Share Issue/Capital Change
臨時報告書
Japanese 215.5 KB
2025-06-19 02:04
Major Shareholding Notification
臨時報告書
Japanese 23.2 KB
2025-06-04 09:05
M&A Activity
訂正意見表明報告書
Japanese 171.8 KB
2025-05-08 08:56
Regulatory News Service
意見表明報告書
Japanese 373.9 KB
2025-03-31 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 24.8 KB
2025-03-27 07:23
Governance Information
内部統制報告書-第133期(2024/01/01-2024/12/31)
Japanese 24.0 KB
2025-03-27 07:22
Registration Form
確認書
Japanese 9.3 KB
2025-03-27 07:18
Annual Report
有価証券報告書-第133期(2024/01/01-2024/12/31)
Japanese 1.0 MB
2024-08-01 03:06
Interim Report
確認書
Japanese 9.2 KB
2024-08-01 03:05
Interim Report
半期報告書-第133期(2024/01/01-2024/12/31)
Japanese 187.0 KB
2024-04-26 08:07
Report Publication Announcement
確認書
Japanese 9.2 KB
2024-04-26 08:06
Quarterly Report
四半期報告書-第133期第1四半期(2024/01/01-2024/03/31)
Japanese 143.5 KB
2024-03-29 07:17
Post-Annual General Meeting Information
臨時報告書
Japanese 39.3 KB

Automate Your Workflow. Get a real-time feed of all TORII PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TORII PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TORII PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Shattuck Labs, Inc. Logo
Clinical-stage biotech developing novel biologic medicines for inflammatory & autoimmune diseases.
United States of America
STTK
Shedir Pharma Group Logo
Develops and sells pharmaceutical, nutraceutical, and dermo-cosmetic products in Italy & Spain.
Italy
SHE
SHIELD THERAPEUTICS PLC Logo
Commercializing a novel oral therapy for adults with iron deficiency.
United Kingdom
STX
SHINPOONG PHARMACEUTICAL CO.,LTD Logo
R&D-driven pharma firm making APIs, finished drugs, and medical products for global markets.
South Korea
019170
Shionogi & Co.,Ltd. Logo
A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.
Japan
4507
Shuttle Pharmaceuticals Holdings, Inc. Logo
Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.
United States of America
SHPH
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland
SFZN
SIGA TECHNOLOGIES INC Logo
Develops antiviral drugs for global health security against biothreats and infectious diseases.
United States of America
SIGA
Silexion Therapeutics Corp Logo
Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.
United States of America
SLXN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea
215600

Talk to a Data Expert

Have a question? We'll get back to you promptly.